SNCA and Parkinson disease: The mechanism underlying the SNCA SNP rs356219 needs further studies to fully understand its pathogenicity but it appears here, in line with the critical dose hypothesis, that different levels of alpha-synuclein in specific brain regions may contribute not only to the risk to develop sporadic PD but also influence the therapeutic outcomes.